APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ophthalmic Corticosteroid

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Ophthalmic Corticosteroid Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchOphthalmic Corticosteroid Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Ophthalmic Corticosteroid Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Ophthalmic Corticosteroid Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ophthalmic Corticosteroid Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Ophthalmic Corticosteroid Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Ophthalmic Corticosteroid market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Ophthalmic Corticosteroid include Novartis AG, Pfizer, GlaxoSmithKline, Bayer AG, Sun Pharmaceutical, Regeneron Pharmaceuticals, Orchidia, Innovative Pharmaceuticals and General Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ophthalmic Corticosteroid, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ophthalmic Corticosteroid, also provides the revenue of main regions and countries. Of the upcoming market potential for Ophthalmic Corticosteroid, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ophthalmic Corticosteroid revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ophthalmic Corticosteroid market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Ophthalmic Corticosteroid revenue, projected growth trends, production technology, application and end-user industry.

Ophthalmic Corticosteroid Segment by Company

Novartis AG

Pfizer

GlaxoSmithKline

Bayer AG

Sun Pharmaceutical

Regeneron Pharmaceuticals

Orchidia

Innovative Pharmaceuticals

General Pharmaceuticals

Genentech

Bausch Health

Bausch and Lomb

Allergan

Alimera Sciences

Ajanta Pharma

Ophthalmic Corticosteroid Segment by Type

Dexamethasone

Difluprednate

Fluorometholone

Loteprednol

Others

Ophthalmic Corticosteroid Segment by Application

Hospital Pharmacies

Research Institute

Online Pharmacies

Retail Pharmacies

Others

Ophthalmic Corticosteroid Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic Corticosteroid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic Corticosteroid and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic Corticosteroid.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Ophthalmic Corticosteroid in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Ophthalmic Corticosteroid company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ophthalmic Corticosteroid revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ophthalmic Corticosteroid Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Dexamethasone Major Player Table 3. Difluprednate Major Player Table 4. Fluorometholone Major Player Table 5. Loteprednol Major Player Table 6. Others Major Player Table 7. Global Ophthalmic Corticosteroid Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Pharmacies Major Player Table 9. Research Institute Major Player Table 10. Online Pharmacies Major Player Table 11. Retail Pharmacies Major Player Table 12. Others Major Player Table 13. Ophthalmic Corticosteroid Industry Trends Table 14. Ophthalmic Corticosteroid Industry Drivers Table 15. Ophthalmic Corticosteroid Industry Opportunities and Challenges Table 16. Ophthalmic Corticosteroid Industry Restraints Table 17. Global Ophthalmic Corticosteroid Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Ophthalmic Corticosteroid Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Ophthalmic Corticosteroid Market Share by Region (2021-2026) Table 20. Global Ophthalmic Corticosteroid Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Ophthalmic Corticosteroid Market Share by Region (2027-2032) Table 22. Global Ophthalmic Corticosteroid Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Ophthalmic Corticosteroid Revenue Market Share by Players (2021-2026) Table 24. Global Ophthalmic Corticosteroid Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Ophthalmic Corticosteroid Key Players Headquarters & Area Served Table 26. Global Ophthalmic Corticosteroid Players, Product Type & Application Table 27. Global Ophthalmic Corticosteroid Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Ophthalmic Corticosteroid by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Ophthalmic Corticosteroid Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Ophthalmic Corticosteroid Revenue Market Share by Type (2021-2026) Table 34. Global Ophthalmic Corticosteroid Revenue Market Share by Type (2027-2032) Table 35. Global Ophthalmic Corticosteroid Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Ophthalmic Corticosteroid Revenue Market Share by Application (2021-2026) Table 39. Global Ophthalmic Corticosteroid Revenue Market Share by Application (2027-2032) Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis AG Ophthalmic Corticosteroid Product Portfolio Table 44. Novartis AG Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer Ophthalmic Corticosteroid Product Portfolio Table 49. Pfizer Recent Development Table 50. GlaxoSmithKline Company Information Table 51. GlaxoSmithKline Business Overview Table 52. GlaxoSmithKline Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio Table 54. GlaxoSmithKline Recent Development Table 55. Bayer AG Company Information Table 56. Bayer AG Business Overview Table 57. Bayer AG Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bayer AG Ophthalmic Corticosteroid Product Portfolio Table 59. Bayer AG Recent Development Table 60. Sun Pharmaceutical Company Information Table 61. Sun Pharmaceutical Business Overview Table 62. Sun Pharmaceutical Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio Table 64. Sun Pharmaceutical Recent Development Table 65. Regeneron Pharmaceuticals Company Information Table 66. Regeneron Pharmaceuticals Business Overview Table 67. Regeneron Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 69. Regeneron Pharmaceuticals Recent Development Table 70. Orchidia Company Information Table 71. Orchidia Business Overview Table 72. Orchidia Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Orchidia Ophthalmic Corticosteroid Product Portfolio Table 74. Orchidia Recent Development Table 75. Innovative Pharmaceuticals Company Information Table 76. Innovative Pharmaceuticals Business Overview Table 77. Innovative Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 79. Innovative Pharmaceuticals Recent Development Table 80. General Pharmaceuticals Company Information Table 81. General Pharmaceuticals Business Overview Table 82. General Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 84. General Pharmaceuticals Recent Development Table 85. Genentech Company Information Table 86. Genentech Business Overview Table 87. Genentech Ophthalmic Corticosteroid Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Genentech Ophthalmic Corticosteroid Product Portfolio Table 89. Genentech Recent Development Table 90. Bausch Health Company Information Table 91. Bausch Health Business Overview Table 92. Bausch Health Ophthalmic Corticosteroid Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bausch Health Ophthalmic Corticosteroid Product Portfolio Table 94. Bausch Health Recent Development Table 95. Bausch and Lomb Company Information Table 96. Bausch and Lomb Business Overview Table 97. Bausch and Lomb Ophthalmic Corticosteroid Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio Table 99. Bausch and Lomb Recent Development Table 100. Allergan Company Information Table 101. Allergan Business Overview Table 102. Allergan Ophthalmic Corticosteroid Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Allergan Ophthalmic Corticosteroid Product Portfolio Table 104. Allergan Recent Development Table 105. Alimera Sciences Company Information Table 106. Alimera Sciences Business Overview Table 107. Alimera Sciences Ophthalmic Corticosteroid Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Alimera Sciences Ophthalmic Corticosteroid Product Portfolio Table 109. Alimera Sciences Recent Development Table 110. Ajanta Pharma Company Information Table 111. Ajanta Pharma Business Overview Table 112. Ajanta Pharma Ophthalmic Corticosteroid Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio Table 114. Ajanta Pharma Recent Development Table 115. North America Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Ophthalmic Corticosteroid Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Ophthalmic Corticosteroid Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Ophthalmic Corticosteroid Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Ophthalmic Corticosteroid Revenue by Country (US$ Million) & (2027-2032) Table 129. China Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 130. China Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 131. China Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 132. China Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Ophthalmic Corticosteroid Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Ophthalmic Corticosteroid Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Ophthalmic Corticosteroid Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Ophthalmic Corticosteroid Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Ophthalmic Corticosteroid Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Ophthalmic Corticosteroid Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Ophthalmic Corticosteroid Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Ophthalmic Corticosteroid Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Ophthalmic Corticosteroid Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Ophthalmic Corticosteroid Image Figure 2. Global Ophthalmic Corticosteroid Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ophthalmic Corticosteroid Market Size Share 2021 VS 2025 VS 2032 Figure 4. Dexamethasone Image Figure 5. Difluprednate Image Figure 6. Fluorometholone Image Figure 7. Loteprednol Image Figure 8. Others Image Figure 9. Global Ophthalmic Corticosteroid Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Ophthalmic Corticosteroid Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Research Institute Image Figure 13. Online Pharmacies Image Figure 14. Retail Pharmacies Image Figure 15. Others Image Figure 16. Global Ophthalmic Corticosteroid Market Size (US$ Million) & (2021-2032) Figure 17. Global Ophthalmic Corticosteroid Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Ophthalmic Corticosteroid Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Ophthalmic Corticosteroid Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Ophthalmic Corticosteroid Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Ophthalmic Corticosteroid Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Ophthalmic Corticosteroid Revenue Market Share by Type (2021-2032) Figure 24. Global Ophthalmic Corticosteroid Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Ophthalmic Corticosteroid Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Ophthalmic Corticosteroid Revenue Market Share by Application (2021-2032) Figure 27. North America Ophthalmic Corticosteroid Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Ophthalmic Corticosteroid Revenue Share by Type (2021-2032) Figure 29. North America Ophthalmic Corticosteroid Revenue Share by Application (2021-2032) Figure 30. North America Ophthalmic Corticosteroid Revenue Share by Country (2021-2032) Figure 31. United States Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Ophthalmic Corticosteroid Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Ophthalmic Corticosteroid Revenue Share by Type (2021-2032) Figure 36. Europe Ophthalmic Corticosteroid Revenue Share by Application (2021-2032) Figure 37. Europe Ophthalmic Corticosteroid Revenue Share by Country (2021-2032) Figure 38. Germany Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Ophthalmic Corticosteroid Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Ophthalmic Corticosteroid Revenue Share by Type (2021-2032) Figure 48. China Ophthalmic Corticosteroid Revenue Share by Application (2021-2032) Figure 49. Asia Ophthalmic Corticosteroid Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Ophthalmic Corticosteroid Revenue Share by Type (2021-2032) Figure 51. Asia Ophthalmic Corticosteroid Revenue Share by Application (2021-2032) Figure 52. Asia Ophthalmic Corticosteroid Revenue Share by Region (2021-2032) Figure 53. Japan Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Ophthalmic Corticosteroid Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Ophthalmic Corticosteroid Revenue Share by Type (2021-2032) Figure 61. SAMEA Ophthalmic Corticosteroid Revenue Share by Application (2021-2032) Figure 62. SAMEA Ophthalmic Corticosteroid Revenue Share by Country (2021-2032) Figure 63. Brazil Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Ophthalmic Corticosteroid Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Dexamethasone
  • Difluprednate
  • Fluorometholone
  • Loteprednol
  • Others
Applications
  • Hospital Pharmacies
  • Research Institute
  • Online Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Novartis AG
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • Sun Pharmaceutical
  • Regeneron Pharmaceuticals
  • Orchidia
  • Innovative Pharmaceuticals
  • General Pharmaceuticals
  • Genentech
  • Bausch Health
  • Bausch and Lomb
  • Allergan
  • Alimera Sciences
  • Ajanta Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ophthalmic Corticosteroid Market by Type
  3. 1.2.1 Global Ophthalmic Corticosteroid Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Dexamethasone
  5. 1.2.3 Difluprednate
  6. 1.2.4 Fluorometholone
  7. 1.2.5 Loteprednol
  8. 1.2.6 Others
  9. 1.3 Ophthalmic Corticosteroid Market by Application
  10. 1.3.1 Global Ophthalmic Corticosteroid Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Research Institute
  13. 1.3.4 Online Pharmacies
  14. 1.3.5 Retail Pharmacies
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Ophthalmic Corticosteroid Market Dynamics
  1. 2.1 Ophthalmic Corticosteroid Industry Trends
  2. 2.2 Ophthalmic Corticosteroid Industry Drivers
  3. 2.3 Ophthalmic Corticosteroid Industry Opportunities and Challenges
  4. 2.4 Ophthalmic Corticosteroid Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Ophthalmic Corticosteroid Market Perspective (2021-2032)
  2. 3.2 Global Ophthalmic Corticosteroid Growth Trends by Region
  3. 3.2.1 Global Ophthalmic Corticosteroid Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ophthalmic Corticosteroid Market Size by Region (2021-2026)
  5. 3.2.3 Global Ophthalmic Corticosteroid Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Ophthalmic Corticosteroid Revenue by Players
  2. 4.1.1 Global Ophthalmic Corticosteroid Revenue by Players (2021-2026)
  3. 4.1.2 Global Ophthalmic Corticosteroid Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Ophthalmic Corticosteroid Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ophthalmic Corticosteroid Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Ophthalmic Corticosteroid Key Players Headquarters & Area Served
  7. 4.4 Global Ophthalmic Corticosteroid Players, Product Type & Application
  8. 4.5 Global Ophthalmic Corticosteroid Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Ophthalmic Corticosteroid Market CR5 and HHI
  11. 4.6.3 2025 Ophthalmic Corticosteroid Tier 1, Tier 2, and Tier 3
5 Ophthalmic Corticosteroid Market Size by Type
  1. 5.1 Global Ophthalmic Corticosteroid Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 5.3 Global Ophthalmic Corticosteroid Revenue Market Share by Type (2021-2032)
6 Ophthalmic Corticosteroid Market Size by Application
  1. 6.1 Global Ophthalmic Corticosteroid Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  3. 6.3 Global Ophthalmic Corticosteroid Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Ophthalmic Corticosteroid Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Ophthalmic Corticosteroid Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GlaxoSmithKline
  14. 7.3.1 GlaxoSmithKline Company Information
  15. 7.3.2 GlaxoSmithKline Business Overview
  16. 7.3.3 GlaxoSmithKline Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio
  18. 7.3.5 GlaxoSmithKline Recent Developments
  19. 7.4 Bayer AG
  20. 7.4.1 Bayer AG Company Information
  21. 7.4.2 Bayer AG Business Overview
  22. 7.4.3 Bayer AG Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bayer AG Ophthalmic Corticosteroid Product Portfolio
  24. 7.4.5 Bayer AG Recent Developments
  25. 7.5 Sun Pharmaceutical
  26. 7.5.1 Sun Pharmaceutical Company Information
  27. 7.5.2 Sun Pharmaceutical Business Overview
  28. 7.5.3 Sun Pharmaceutical Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio
  30. 7.5.5 Sun Pharmaceutical Recent Developments
  31. 7.6 Regeneron Pharmaceuticals
  32. 7.6.1 Regeneron Pharmaceuticals Company Information
  33. 7.6.2 Regeneron Pharmaceuticals Business Overview
  34. 7.6.3 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  36. 7.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 7.7 Orchidia
  38. 7.7.1 Orchidia Company Information
  39. 7.7.2 Orchidia Business Overview
  40. 7.7.3 Orchidia Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Orchidia Ophthalmic Corticosteroid Product Portfolio
  42. 7.7.5 Orchidia Recent Developments
  43. 7.8 Innovative Pharmaceuticals
  44. 7.8.1 Innovative Pharmaceuticals Company Information
  45. 7.8.2 Innovative Pharmaceuticals Business Overview
  46. 7.8.3 Innovative Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  48. 7.8.5 Innovative Pharmaceuticals Recent Developments
  49. 7.9 General Pharmaceuticals
  50. 7.9.1 General Pharmaceuticals Company Information
  51. 7.9.2 General Pharmaceuticals Business Overview
  52. 7.9.3 General Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  53. 7.9.4 General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  54. 7.9.5 General Pharmaceuticals Recent Developments
  55. 7.10 Genentech
  56. 7.10.1 Genentech Company Information
  57. 7.10.2 Genentech Business Overview
  58. 7.10.3 Genentech Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Genentech Ophthalmic Corticosteroid Product Portfolio
  60. 7.10.5 Genentech Recent Developments
  61. 7.11 Bausch Health
  62. 7.11.1 Bausch Health Company Information
  63. 7.11.2 Bausch Health Business Overview
  64. 7.11.3 Bausch Health Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bausch Health Ophthalmic Corticosteroid Product Portfolio
  66. 7.11.5 Bausch Health Recent Developments
  67. 7.12 Bausch and Lomb
  68. 7.12.1 Bausch and Lomb Company Information
  69. 7.12.2 Bausch and Lomb Business Overview
  70. 7.12.3 Bausch and Lomb Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio
  72. 7.12.5 Bausch and Lomb Recent Developments
  73. 7.13 Allergan
  74. 7.13.1 Allergan Company Information
  75. 7.13.2 Allergan Business Overview
  76. 7.13.3 Allergan Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Allergan Ophthalmic Corticosteroid Product Portfolio
  78. 7.13.5 Allergan Recent Developments
  79. 7.14 Alimera Sciences
  80. 7.14.1 Alimera Sciences Company Information
  81. 7.14.2 Alimera Sciences Business Overview
  82. 7.14.3 Alimera Sciences Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Alimera Sciences Ophthalmic Corticosteroid Product Portfolio
  84. 7.14.5 Alimera Sciences Recent Developments
  85. 7.15 Ajanta Pharma
  86. 7.15.1 Ajanta Pharma Company Information
  87. 7.15.2 Ajanta Pharma Business Overview
  88. 7.15.3 Ajanta Pharma Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio
  90. 7.15.5 Ajanta Pharma Recent Developments
8 North America
  1. 8.1 North America Ophthalmic Corticosteroid Revenue (2021-2032)
  2. 8.2 North America Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 8.2.1 North America Ophthalmic Corticosteroid Revenue by Type (2021-2026)
  4. 8.2.2 North America Ophthalmic Corticosteroid Revenue by Type (2027-2032)
  5. 8.3 North America Ophthalmic Corticosteroid Revenue Share by Type (2021-2032)
  6. 8.4 North America Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  7. 8.4.1 North America Ophthalmic Corticosteroid Revenue by Application (2021-2026)
  8. 8.4.2 North America Ophthalmic Corticosteroid Revenue by Application (2027-2032)
  9. 8.5 North America Ophthalmic Corticosteroid Revenue Share by Application (2021-2032)
  10. 8.6 North America Ophthalmic Corticosteroid Revenue by Country
  11. 8.6.1 North America Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Ophthalmic Corticosteroid Revenue by Country (2021-2026)
  13. 8.6.3 North America Ophthalmic Corticosteroid Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Ophthalmic Corticosteroid Revenue (2021-2032)
  2. 9.2 Europe Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 9.2.1 Europe Ophthalmic Corticosteroid Revenue by Type (2021-2026)
  4. 9.2.2 Europe Ophthalmic Corticosteroid Revenue by Type (2027-2032)
  5. 9.3 Europe Ophthalmic Corticosteroid Revenue Share by Type (2021-2032)
  6. 9.4 Europe Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  7. 9.4.1 Europe Ophthalmic Corticosteroid Revenue by Application (2021-2026)
  8. 9.4.2 Europe Ophthalmic Corticosteroid Revenue by Application (2027-2032)
  9. 9.5 Europe Ophthalmic Corticosteroid Revenue Share by Application (2021-2032)
  10. 9.6 Europe Ophthalmic Corticosteroid Revenue by Country
  11. 9.6.1 Europe Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Ophthalmic Corticosteroid Revenue by Country (2021-2026)
  13. 9.6.3 Europe Ophthalmic Corticosteroid Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Ophthalmic Corticosteroid Revenue (2021-2032)
  2. 10.2 China Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 10.2.1 China Ophthalmic Corticosteroid Revenue by Type (2021-2026)
  4. 10.2.2 China Ophthalmic Corticosteroid Revenue by Type (2027-2032)
  5. 10.3 China Ophthalmic Corticosteroid Revenue Share by Type (2021-2032)
  6. 10.4 China Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  7. 10.4.1 China Ophthalmic Corticosteroid Revenue by Application (2021-2026)
  8. 10.4.2 China Ophthalmic Corticosteroid Revenue by Application (2027-2032)
  9. 10.5 China Ophthalmic Corticosteroid Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ophthalmic Corticosteroid Revenue (2021-2032)
  2. 11.2 Asia Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 11.2.1 Asia Ophthalmic Corticosteroid Revenue by Type (2021-2026)
  4. 11.2.2 Asia Ophthalmic Corticosteroid Revenue by Type (2027-2032)
  5. 11.3 Asia Ophthalmic Corticosteroid Revenue Share by Type (2021-2032)
  6. 11.4 Asia Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  7. 11.4.1 Asia Ophthalmic Corticosteroid Revenue by Application (2021-2026)
  8. 11.4.2 Asia Ophthalmic Corticosteroid Revenue by Application (2027-2032)
  9. 11.5 Asia Ophthalmic Corticosteroid Revenue Share by Application (2021-2032)
  10. 11.6 Asia Ophthalmic Corticosteroid Revenue by Country
  11. 11.6.1 Asia Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Ophthalmic Corticosteroid Revenue by Country (2021-2026)
  13. 11.6.3 Asia Ophthalmic Corticosteroid Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ophthalmic Corticosteroid Revenue (2021-2032)
  2. 12.2 SAMEA Ophthalmic Corticosteroid Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Ophthalmic Corticosteroid Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Ophthalmic Corticosteroid Revenue by Type (2027-2032)
  5. 12.3 SAMEA Ophthalmic Corticosteroid Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Ophthalmic Corticosteroid Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Ophthalmic Corticosteroid Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Ophthalmic Corticosteroid Revenue by Application (2027-2032)
  9. 12.5 SAMEA Ophthalmic Corticosteroid Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Ophthalmic Corticosteroid Revenue by Country
  11. 12.6.1 SAMEA Ophthalmic Corticosteroid Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Ophthalmic Corticosteroid Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Ophthalmic Corticosteroid Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst